InvestWiser

Carasent ASA

CARANasdaq StockholmHealthcareMarket value 1.6 bn SEK
24.45SEK −2.6%
last day · Price as of 20 November 2026

The answer first

Does Carasent beat the market?

No, Carasent has not beaten the market over the last year.

Carasent−9.4%Stockholm (OMXSGI)+13.6%
  • The ranking · Quality, value and trend combined

    Better than 48% of Nordic stocks

    • Quality65
    • Value27
    • Trend62

    No. 62 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash Carasent keeps must grow about 11% a year for 10 years.

Max for seven days

Follow Carasent with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Carasent

From today, at a price of 24.45 SEK. Write why you follow Carasent, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Carasent

Your first answer is free, no account needed.

Do you own Carasent, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Carasent and a few more. Free, no card.

Past year against the exchange and Super Stock
Carasent−9.4%Stockholm (OMXSGI)+13.6%Super Stock+45.3%
19 November 202520 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Carasent has fallen 9.4% over the past year, including dividends.
  • Overall, Carasent ranks better than 48% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 77.0%. The price is 43.2% below its peak now.

What do analysts think of Carasent?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

48

Quality, value and trend together. Better than 48% of Nordic stocks.

No. 62 of 195 in healthcare

Quality65
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 98 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.05
  • Asset turnoverSales divided by everything the company owns0.40
  • Return on equityProfit divided by equity+4.9%
  • Cash conversionOperating cash flow divided by profit2.39

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value27
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 78 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50

  • P/BPrice divided by equity2.0
  • P/SPrice divided by sales4.1
  • P/EPrice divided by earnings40.9
  • P/CFPrice divided by operating cash flow17.1

The ranking is built on P/E, P/B and P/S.

Trend62
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 60 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−3.2%
  • 6 months+5.6%
  • 9 months+6.3%
  • 12 months−9.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−9.3%
3 years, per year
−12.4%
5 years, per year
–
Year to date
−10.9%
Largest fall, 3 years
−77.0%
From a peak to the bottom
From the peak now
−43.2%
How far the price is from the peak
Volatility, 1 year
29.0%
How much the price swings over a year
Beta, 1 year
0.56
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Carasent

8 funds we follow own Carasent. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden7

From the funds' latest known holdings.

About Carasent

Carasent ASA is a company in healthcare, listed on Nasdaq Stockholm. By market value, Carasent is number 33 of 137 companies in healthcare on Nasdaq Stockholm. Carasent has not paid a dividend in the past twelve months. Of the three measures in the ranking, Carasent is strongest on quality, better than 65% of Nordic stocks. The share trades in SEK. It has around 230 employees.

Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.

See the full analysis of Carasent.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market